Revisional Surgery of One Anastomosis Gastric Bypass for Severe Protein-Energy Malnutrition.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
06 Jun 2022
Historique:
received: 26 04 2022
revised: 01 06 2022
accepted: 03 06 2022
entrez: 10 6 2022
pubmed: 11 6 2022
medline: 14 6 2022
Statut: epublish

Résumé

One anastomosis gastric bypass (OAGB) is safe and effective. Its strong malabsorptive component might cause severe protein-energy malnutrition (PEM), necessitating revisional surgery. We aimed to evaluate the safety and outcomes of OAGB revision for severe PEM. This was a single-center retrospective analysis of OAGB patients undergoing revision for severe PEM (2015-2021). Perioperative data and outcomes were retrieved. Ten patients underwent revision for severe PEM. Our center's incidence is 0.63% (9/1425 OAGB). All patients were symptomatic. Median (interquartile range) EWL and lowest albumin were 103.7% (range 57.6, 114) and 24 g/dL (range 19, 27), respectively, and 8/10 patients had significant micronutrient deficiencies. Before revision, nutritional optimization was undertaken. Median OAGB to revision interval was 18.4 months (range 15.7, 27.8). Median BPL length was 200 cm (range 177, 227). Reversal ( Revisional surgery of OAGB for severe PEM is feasible and safe after nutritional optimization. Our results suggest that the type of revision may be an important factor for PEM resolution. Comparative studies are needed to define the role of each revisional option.

Sections du résumé

BACKGROUND BACKGROUND
One anastomosis gastric bypass (OAGB) is safe and effective. Its strong malabsorptive component might cause severe protein-energy malnutrition (PEM), necessitating revisional surgery. We aimed to evaluate the safety and outcomes of OAGB revision for severe PEM.
METHODS METHODS
This was a single-center retrospective analysis of OAGB patients undergoing revision for severe PEM (2015-2021). Perioperative data and outcomes were retrieved.
RESULTS RESULTS
Ten patients underwent revision for severe PEM. Our center's incidence is 0.63% (9/1425 OAGB). All patients were symptomatic. Median (interquartile range) EWL and lowest albumin were 103.7% (range 57.6, 114) and 24 g/dL (range 19, 27), respectively, and 8/10 patients had significant micronutrient deficiencies. Before revision, nutritional optimization was undertaken. Median OAGB to revision interval was 18.4 months (range 15.7, 27.8). Median BPL length was 200 cm (range 177, 227). Reversal (
CONCLUSIONS CONCLUSIONS
Revisional surgery of OAGB for severe PEM is feasible and safe after nutritional optimization. Our results suggest that the type of revision may be an important factor for PEM resolution. Comparative studies are needed to define the role of each revisional option.

Identifiants

pubmed: 35684155
pii: nu14112356
doi: 10.3390/nu14112356
pmc: PMC9183067
pii:
doi:

Substances chimiques

Albumins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Surg Obes Relat Dis. 2018 Feb;14(2):181-185
pubmed: 29198751
Surg Obes Relat Dis. 2015 Mar-Apr;11(2):328-34
pubmed: 25614357
Obes Surg. 2020 Apr;30(4):1258-1264
pubmed: 31845082
Visc Med. 2019 Oct;35(5):305-311
pubmed: 31768394
J Res Med Sci. 2020 Jun 30;25:62
pubmed: 33088299
Obes Surg. 2016 May;26(5):933-40
pubmed: 26341086
Obes Surg. 2019 Sep;29(9):3062-3070
pubmed: 31209832
Surg Obes Relat Dis. 2022 Feb;18(2):225-232
pubmed: 34794865
Surg Obes Relat Dis. 2020 Feb;16(2):175-247
pubmed: 31917200
Langenbecks Arch Surg. 2017 Dec;402(8):1263-1270
pubmed: 28803414
BMC Surg. 2020 Feb 26;20(1):37
pubmed: 32101137
Surg Obes Relat Dis. 2019 Dec;15(12):2038-2044
pubmed: 31734066
Surg Obes Relat Dis. 2021 May;17(5):968-975
pubmed: 33619007
Isr Med Assoc J. 2019 Dec;21(12):823-828
pubmed: 31814347
Obes Surg. 2016 Sep;26(9):2014-2021
pubmed: 26781694
Obes Surg. 2015 Jun;25(6):951-8
pubmed: 25585612
Obes Surg. 2017 May;27(5):1153-1167
pubmed: 27783366
Obes Surg. 2018 Sep;28(9):2956-2967
pubmed: 29995293
Obes Surg. 2022 Feb;32(2):256-265
pubmed: 34973123
Obes Surg. 2018 Nov;28(11):3439-3445
pubmed: 30032419
Clin Obes. 2018 Jun;8(3):159-169
pubmed: 29573175
Obes Surg. 2020 May;30(5):1625-1634
pubmed: 32152841
Obes Surg. 2020 Oct;30(10):3685-3694
pubmed: 32458362
Obes Surg. 2021 Apr;31(4):1411-1421
pubmed: 33517557
Obes Surg. 2005 Oct;15(9):1304-8
pubmed: 16259892
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Obes Surg. 2021 Jul;31(7):3251-3278
pubmed: 33939059
Surg Obes Relat Dis. 2021 Aug;17(8):1489-1496
pubmed: 34045165
Surg Endosc. 2020 Jun;34(6):2332-2358
pubmed: 32328827
Int J Surg. 2019 Sep;69:13-18
pubmed: 31299430
Obes Surg. 2020 Apr;30(4):1564-1573
pubmed: 31982993
Surg Technol Int. 2020 Nov 28;37:57-61
pubmed: 33180956

Auteurs

Adam Abu-Abeid (A)

Division of General Surgery, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv 6423906, Israel.
Sackler's Faculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.

Or Goren (O)

Sackler's Faculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.
Division of Anesthesiology, Pain and Intensive Care, Tel Aviv Medical Center, Tel Aviv 6423906, Israel.

Shai Meron Eldar (SM)

Division of General Surgery, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv 6423906, Israel.
Sackler's Faculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.

Antonio Vitiello (A)

Advanced Biomedical Sciences Department, Naples "Federico II" University, AOU "Federico II"-Via S. Pansini 5, 80131 Napoli, Italy.

Giovanna Berardi (G)

Advanced Biomedical Sciences Department, Naples "Federico II" University, AOU "Federico II"-Via S. Pansini 5, 80131 Napoli, Italy.

Guy Lahat (G)

Division of General Surgery, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv 6423906, Israel.
Sackler's Faculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.

Danit Dayan (D)

Division of General Surgery, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv 6423906, Israel.
Sackler's Faculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH